SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Roger's 1997 Short Picks -- Ignore unavailable to you. Want to Upgrade?

To: Sam Golden who wrote (8148)12/11/1997 2:12:00 AM
From: Bill Wexler  Read Replies (1) | Respond to of 9285
 
<<Bill, Tell me something. Is this the main thing in their pipeline. Last time I have heard phentolamine mentioned was 20 years ago in pharmacy school. This has to be a joke, right?>>

No joke. This is the only active ingredient.

There is also compelling evidence that they obfuscated phase II results.



To: Sam Golden who wrote (8148)12/11/1997 2:42:00 AM
From: BDR  Read Replies (1) | Respond to of 9285
 
<BTW there has been several new drugs out Caverject and most recently MUSE
by major Drug companies that are rather sucessfull in their class>

Take a look at a chart of VVUS for 1997. Resembles a NPTM tracing. I wouldn't call it (MUSE) successful just yet.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News